Pneumococcal polysaccharide-based vaccines are effective in preventing pneumococcus infection; however, some drawbacks preclude their widespread use in developing and undeveloped countries. Here, we evaluated the protective effects of ATP-dependent caseinolytic protease (ClpP), pneumolysin mutant (⌬A146 Ply), putative lipoate-protein ligase (Lpl), or combinations thereof against pneumococcal infections in mice. Vaccinated mice were intraperitoneally and/or intranasally challenged with different pneumococcal strains. In intraperitoneal challenge models with pneumococcal strain D39 (serotype 2), the most striking protection was obtained with the combination of the three antigens. Similarly, with the intranasal challenge models, (i) additive clearance of bacteria in lungs was observed for the combination of the three antigens and (ii) a combination vaccine conferred complete protection against intranasal infections of three of the four most common pneumococcal strains (serotypes 14, 19F, and 23F) and 80% protection for pneumococcal strain 6B. Even so, immunity to this combination could confer protection against pneumococcal infection with a mixture of four serotypes. Our results showed that the combination vaccine was as effective as the currently used vaccines (PCV7 and PPV23). These results indicate that system immunization with the combination of pneumococcal antigens could provide an additive and broad protection against Streptococcus pneumoniae in pneumonia and sepsis infection models.
Streptococcus pneumoniae (pneumococcus) commonly colonizes the upper respiratory tract asymptomatically and was estimated, in 2005, to kill 1.6 million people every year, most of whom were children aged Ͻ5 years in developing and undeveloped countries (36) . As far as we know, 91 capsular polysaccharide serotypes have been identified in S. pneumoniae (33) ; among these, serotypes 23F, 19F, 14, and 6B are the four most epidemic strains worldwide (2, 5, 15, 17, 25, 26, 29) . Moreover, and of recent concern, the widespread use of antibiotics, leading to the development of antibiotic resistance or multidrug resistance against S. pneumoniae, is increasing (9, 12, 26) .
Heptavalent protein-polysaccharide conjugate vaccine (PCV7) and 23-valent pneumococcal polysaccharide vaccine (PPV23) are the two vaccines currently being used against S. pneumoniae. Both of these vaccines are polysaccharide-based formulations and effective in preventing invasive pneumococcal infections; however, some drawbacks, such as high cost, the limited polysaccharides covered, poor immunogenicity in the very young and the very old, and serotype replacement (22, 24, 26, 36) , limit their wider use.
Alternatively, in an attempt to overcome the disadvantages of polysaccharide-based vaccines, a number of studies have been focusing on the screening and evaluation of proteinbased vaccine candidates. Pneumococcal protein vaccine candidates, such as nontoxic pneumolysin derivates, pneumococcal surface proteins (PspA and PspC), pneumococcal surface adhesin (PsaA), and ATP-dependent caseinolytic proteases (ClpP), have been studied and shown to provide protection against S. pneumoniae. In addition, another surface protein, putative lipoate-protein ligase (Lpl), has been suggested to be a vaccine candidate, which could effectively elicit a high IgG titer and reduce the blood bacterial load (30) . These vaccine candidates are shared by all S. pneumoniae. Of note, it is generally recognized that pneumolysin localized in the cytoplast in a soluble monomer, and its release was dependent on or independent of autolysin (3, 4, 18, 19) . A recent study, which showed that pneumolysin was also partially localized on the cell wall (34) , strengthened its utility as a vaccine candidate. Additive protections were obtained with combinations of these protein candidates. However, previous evaluations have been based only on intraperitoneal challenge models of pneumococcal disease and were not, to our knowledge, been performed in pneumonia models (7, 10, 13, 20, 23, 30, 37) . In the present study, putative lipoate-protein ligase (Lpl), ClpP, and Ply toxoid were expressed, purified, and confirmed to express on all of the pneumococcal strains used here. A focal pneumococcal pneumonia model, mimicking the natural pneumococcal infection, was used to evaluate pneumococci on lung colonization. We also set up models of invasive diseases, which were used to evaluate their systemic protective effects against pneumococcal infections. System vaccination with the then centrifuged for 1 min at 1,000 ϫ g, the supernatant was carefully transferred to 96-well flat-bottom plates, and the absorbance was read at 540 nm.
Challenge of animals. For the intraperitoneal challenge models, at 2 weeks after the last immunization BALB/c mice were administrated the virulent pneumococcal strain D39 at 1,500 times the 50% lethal dose (LD 50 ; 1.5 ϫ 10 5 CFU) or 150 times the LD 50 (2.0 ϫ 10 4 CFU). In the focal pneumonia models, BALB/c mice were intranasally inoculated with pneumococcal strain 31614 (serotype 14, 1.5 ϫ 10 6 CFU) or 31693 (serotype 19F, 10 7 CFU). The lungs were removed at day 5 after challenge and homogenized in PBS. Samples were serially diluted and plated onto blood agar plates, and viable counts were determined after overnight incubation.
For intranasal challenge with pneumococcal strain D39, mice inspired the virulent pneumococcal strain D39 at 10 4 (7. Blood and lung samples of dying mice were collected and suspended in PBS, followed by centrifugation at 750 ϫ g for 10 min. Then, 15 l of the supernatants was plated on blood agar plates, followed by incubation overnight. Several clones with different characteristic were picked and suspended in sterile deionized water for PCR. Primers specific to each serotype were synthesized as described by Brito et al. (8) .
Passive immunization. Antisera from control protein-or combination-immunized animals were prepared from vaccinated mice and subjected to incubation at 56°C for 30 min to inactivate complement. Then, 200 l of antisera (undiluted or 1/15 diluted antisera) was intraperitoneally transferred to animals immediately before infection with pneumococcal strain D39 (600 CFU).
To determine further whether the protective serum component was antigenspecific antibodies, diluted antisera (1/10) were adsorbed either with wild-type strain R6 or with ⌬Lpl R6, ⌬ClpP R6, and ⌬Ply R6 strains, respectively. Briefly, to deprive the serum samples of Lpl-, ClpP-, and Ply-specific antibodies, the sera were adsorbed with wild-type strain R6, whereas to prepare antigen-specific antibodies, the sera were first adsorbed with ⌬Lpl R6, ⌬ClpP R6, and ⌬Ply R6 strains, respectively. The supernatant was obtained after centrifugation, and then was subjected to filter through a 0.2-m-pore-size filter. The resultant sera were equally mixed together, which are referred to here as antigen-specific antibodies. Before passively transfer to mice, ELISA was used to measure antigen-specific IgG titer in sera. Then, 200-l portions of adsorbed antisera were intraperitoneally delivered to BALB/c mice, followed by intraperitoneal infection with pneumococcal strain D39 (600 CFU) immediately. All animals were carefully observed for 21 days.
Construction of ⌬Lpl R6, ⌬ClpP R6, and ⌬Ply R6 mutants. The construction of insertion-deletion mutations of clpP, lpl, and ply (⌬gene::ermB) in S. pneumoniae has been well established by using the long flanking homology polymerase reaction (28) . The 760-bp ermB cassette was PCR amplified with DAM212 and DAM213 from S. pneumoniae CPM8 DNA (11) . Upstream and downstream fragments were PCR amplified with their specific primers (P1 and P3 for upstream fragment; P2 and P4 for downstream fragment; see Table 4 ). Overlap extension was performed to generate the Up-Erm-Dw fusion fragment. The resulting fragment was used to transform S. pneumoniae R6 as described elsewhere (28) . Briefly, pneumococcal strain R6 was exposed to the DNA for 90 min at 37°C after treatment with competence-stimulating peptide. The ensuing culture was plated on blood agar plates containing 0.25 g of erythromycin/ml. Erm insertion at the loci of Lpl, ClpP, and Ply was confirmed by colony PCR.
Statistical analysis. IgG titers and the numbers of CFU (log 10 ) were compared by using the Mann-Whitney U test. For survival studies, data were analyzed by using the log-rank test and the Fisher exact test, and the Mann-Whitney U was used to analyze the difference in median survival time. Values were considered statistically significant at a P value of Ͻ0.05.
RESULTS
Identification of antigen-specific IgG titers. The IgG titers in sera of each protein and PSs were tested at day 35. ELISA analysis of sera from groups of mice immunized with these purified antigens, either singly or in combination, showed an-
tigen-specific antibody responses that were significantly higher than that achieved with control protein (P Ͻ 0.05; Table 1 . Furthermore, comparable IgG titers of each antigen in combinations were detectable. Serum IgG antibodies to PS types 14 and 19F were produced in vaccinated mice with PPV23 and PCV7 (data not shown). Effect of ⌬A146 Ply on hemolysis and hemolysis neutralization is mediated by anti-⌬A146 Ply polyclonal serum. Purified ⌬A146 Ply and wt-Ply were tested for hemolytic activity. Hemolytic activity of wt-Ply was exhibited at concentrations from 5 to 25 ng/ml, whereas no hemolytic activity for human erythrocytes was observed for ⌬A146 Ply, even at concentrations of 500,000 ng/ml. This observation confirmed the previous result that ⌬A146 Ply could not lyse erythrocytes (20) , indicating that ⌬A146 Ply is a safe candidate for further use as a vaccine.
We next tested whether anti-⌬A146 Ply polyclonal serum could prevent wt-Ply from lysing human erythrocytes. wt-Ply exhibited its hemolytic activity in serum diluted 480-fold, and 50% lysis of human red blood cells could be blocked when the pooled serum was diluted 2,840-fold.
Prevention of lung colonization in vaccinated mice. Two focal pneumonia models were set up with two different serotype strains. In the strain 31614 (serotype 14) intranasal infection model, all three proteins were capable of reducing the bacterial load in the lung by Ͼ10-fold compared to control protein-immunized mice, especially Lpl (P Ͻ 0.05; Fig. 1A) . A similar result was observed in the strain 31693 (serotype 19F) infection model. Compared to the control protein, ClpP and Lpl reduced the median bacterial load nearly 100-fold (P ϭ 0.005 and P ϭ 0.01, respectively [data not shown]), and immunity to ⌬A146 Ply was also effective against pneumococcal colonization in lungs, which resulted in a Ͼ10-fold-reduced median bacterial load (P ϭ 0.05 [data not shown]). In a second experiment, the most dramatic protection against lung colonization of strain 31693 was achieved by immunization with the three antigens combined, which reduced the number of lung CFU ϳ10-fold more than that achieved with Lpl plus ClpP and Ͼ20-fold more than those with ClpP plus ⌬A146 Ply and Lpl plus ⌬A146 Ply (P Ͻ 0.05; Fig. 1B) .
Prevention of pneumonia and sepsis in vaccinated mice. In an initial experiment (Table 2) , vaccinated mice were challenged with pneumococcal strain D39 at 1,500 times the LD 50 (1.5 ϫ 10 5 CFU). Sepsis in control mice invariably precedes death. Vaccinated mice survived significantly longer than control mice, except for Lpl group. We observed that 41.7% protection against the 1,500-LD 50 challenge dose was achieved with the three antigens combined (combination vaccine) and with no signs of morbidity in the surviving mice (Table 2) . Under this high-dose challenge, mice that received the threeantigen combination vaccine (combination vaccine) survived significantly longer than those immunized with a single antigen or those immunized with combinations of two antigens (MannWhitney U test, P Ͻ 0.05), except for ⌬A146 Ply plus ClpP. In addition, 70% of combination-vaccinated mice were protected from the challenge with pneumococcal strain D39 at the 150-LD 50 (2.0 ϫ 10 4 CFU) challenge dose, which was as protective as the positive control of 70% protection ( Fig. 2A) . Subse- on October 16, 2017 by guest http://iai.asm.org/ quent study using the less-virulent pneumococcal strain TIGR4 (8 ϫ 10 7 CFU) as the challenge strain showed that Lpl could significantly prolong median survival time to infection; moreover, complete protection was also achieved when mice were vaccinated with the combination vaccine. The median survival time was significantly longer than that achieved by vaccination with ClpP plus ⌬A146 Ply (P Ͻ 0.05; data not shown).
Mice immunized with ⌬A146 Ply regimen were conferred significant protection against pneumococcal strain D39 infection at a 10 4 -LD 50 challenge dose (7.5 ϫ 10 7 CFU), whereas significant protection was not observed in the Lpl and ClpP immunization groups (Table 3 ). A 58.3% level of protection was achieved when mice were vaccinated with ClpP plus ⌬A146 Ply. Similar protection pattern was observed with intranasal challenge with pneumococcal serotype 3 strain 31436 (data not shown). In another set of experiment, 66.7% of the mice immunized with the combination vaccine survived intranasal challenge of pneumococcal strain D39 at 10 3 times the LD 50 (6.0 ϫ 10 6 CFU), which was as protective as PPV23 (Fig.  2B) . Control mice invariably succumbed to infection.
Considering the best protection against pneumococcal infections elicited by the combination vaccine, we next tested whether this vaccine could provide broad protection against different pneumococcal strains (Fig. 3) . Vaccinated BALB/c mice were intranasally challenged with pneumococcal serotype 3, 6B, 14, 19F, 23F or with a combination of four serotypes (6B, 14, 19F, and 23F). Complete protection against serotypes 14, 19F, and 23F was achieved in mice that received the combination vaccine, and 80 and 50% protection was achieved against serotype 6B in mice receiving the combination vaccine and PCV7, respectively. A total of 70% of the mice immunized with the combination vaccine were protected from infection from pneumococcal serotype 3 (virulent strain; 7.5 ϫ 10 6 CFU), whereas only 50% mice survived the challenge in the PPV23-immunized group, but a survival difference was not noted between the two groups. All mice that succumbed to infection were confirmed to have pneumonia and bacteremia due to serotype-specific infection, whereas the surviving mice had no bacteremia and pneumonia at the end of the observation period (Table 5) . We next tested whether the combination vaccine could provide protection against the challenge with a mixture of the four most common pneumococcal serotypes (serotypes 6B, 14, 19F, and The challenge dose was 1.5 ϫ 10 5 CFU (1,500 LD 50 ). b ‫,ء‬ Differences in median survival times between vaccinated groups and control group were analyzed by using the Mann-Whitney U test (P Ͻ 0.05); †, this value is significantly different from the value observed from control mice (P ϭ 0.0373 as determined by the Fisher exact test).
c Calculated as the percentage of living mice at the end of the observation period.
d Significantly longer than those achieved with Lpl plus ⌬A146 Ply and Lpl plus ClpP (Mann-Whitney U test; P Ͻ 0.05).
FIG. 2. Protection of vaccinated mice from pneumococcal strain D39 infections. (A)
BALB/c mice were challenged intraperitoneally with strain D39 at an LD 50 of 150 (2.0 ϫ 10 4 CFU; combination versus PPV23, P ϭ 0.5206; combination versus control, P Ͻ 0.0001) (A) or intranasally with strain D39 at an LD 50 of 10 3 (7.5 ϫ 10 6 CFU; combination versus PPV23, P ϭ 0.9720; combination versus control, P Ͻ 0.0001) (B). The results are represented in survival curves and analyzed by the log-rank test. n refers to the number of animals. For all experiments, control proteinimmunized mice served as negative controls. c Calculated as the percentage of living mice at the end of the observation period. Values significantly different from the value observed with control mice are indicated ‫,ء(‬ P ϭ 0.0137; †, P Ͻ 0.01 ͓Fisher exact test͔). 23F; Fig. 3F ). A 70% protection was achieved in the combination vaccine group, and a 42.8% protection was achieved in the PCV7 group. Colony PCR was used to determine the bacterium serotypes responsible for death in the present study. The dying mice in the combination vaccine group were confirmed to have serotype 6B and 19F infections in the lungs and blood, whereas in the PCV7-vaccinated mice, serotypes 6B, 19F, and 23F were responsible for the deaths. Surprisingly, serotype 14 was not detectable in either groups. All serotype strains were detectable in lung and blood samples in control mice (Fig. 4) .
Passive antiserum transfer from immunized animals provides protection against S. pneumoniae sepsis in mice. Antisera (complement inactivated) from alum-or combination-immunized mice were intraperitoneally transferred to BALB/c mice at the same time they were infected with strain D39 at a 6-LD 50 A total of 60% of the mice were protected from death when passively transferred with 1/15-diluted antisera (Fig. 5A ). Mice that received control antisera were not protected from S. pneumoniae infection.
No protection was seen in infected mice receiving combination-specific antiserum adsorbed with strain R6; in contrast, 50% of the mice survived infection when they received antigenspecific antibodies (Fig. 5B) . Compared to antigen-specific IgG antibodies in sera adsorbed with R6 mutants, ELISA analysis of the combination antisera adsorbed with R6 strains revealed a drastic reduction in the three antigen-specific IgG reactivities (data not shown), indicating that the protection elicited by the combination vaccine was provided by Lpl-, ClpP-, and Plyspecific antibodies in this model.
DISCUSSION
The most dramatic protection against S. pneumoniae sepsis was obtained with a combination of ⌬A146 Ply plus ClpP plus Lpl. Besides. Our observations thus strengthen the conclusion that the combination of pneumococcal antigens could provide additive protection against pneumococcal sepsis (10, 32) . Our study also showed that the protection elicited was antibody mediated, since no protection was seen when antigen-specific antibodies were withdrawn (see Fig. 4 ). Although similar passive protection was not performed here in the intranasal model, we believe that the antibody titer correlates with the protection in either model, because mice boosted twice with ⌬A146 Ply with a high antigen-specific IgG titer survived significantly longer than mice boosted once with ⌬A146 Ply (P Ͻ 0.05 [log-rank analysis]; data not shown).
In the present study, three pneumococcal antigens were used in combinations to test their protective efficacy. Considering the potential antagonism, ELISA was used to reveal whether there were detectable antagonisms between antigens. It has been reported that no immune responses were detected when mice were immunized with ClpP plus Lpl plus ACE097 (30) . In the present study, compatible IgG levels of each protein were detected, which suggests that, on the one hand, ⌬A146 Ply could be used in combination with ClpP plus Lpl and, on the other hand, the immune response failure of their combination may result from the incorporation of ACE097.
Vaccination with each antigen conferred protection in sepsis models and could reduce the pneumococcal load. However, except for pneumolysin, significant protection against intranasal challenge with pneumococcal strain D39 at 7.5 ϫ 10 7 CFU was not observed. A possible explanation for this is that the pneumolysin contributes as a toxin to the overall virulence of the pneumococcus D39 in intranasal infection, so protection elicited by pneumolysin would be more predominant than that achieved by Lpl and ClpP. Also, we may attribute their ineffectiveness to the lethal challenge dosage, which masked the differences between groups in this model, and this in turn emphasizes the importance of immunity to ⌬A146 Ply in this combination.
We observed, in the control mice, a very similar number of CFU both at inoculation and 5 days later. We have also observed that some control mice exhibited clinical symptoms 3 to 4 days postinoculation, e.g., the animals were moribund, but they ultimately survived. It seems that the number of pneumococci initially increased and then decreased afterward because of the animal's natural immunity, so it is possible that after 5 days the CFU count in the lungs may be lower than or equal to the inoculation dosage. In comparison to the CFU in control mice, although there are still ϳ10,000 CFU in single-antigenvaccinated mice, the CFU counts in vaccinated mice were significantly reduced.
Pneumolysin is a very important virulence factor essential for the survival of pneumococci in airway tracts and required for bacterial spread from the lungs to the blood and have a direct cytotoxic effect on alveolar cells (27) . Immunization with PdB, PdA, or even wide-type pneumolysin could confer protection against pneumococcal sepsis (32) . We observed here that ⌬A146 Ply alone elicited protection against the development of bacteremia (data not shown); surprisingly, ⌬A146 Ply alone elicited protection that was as effective as the combination vaccine against intranasal challenge with the D39 strain. Nevertheless, there was evidence that pneumolysin elicited protection against nine pneumococcal serotypes, but protection varied and even failed to protect against one more pneumococcal strain (1) . Moreover, in contrast to a previous study (6) , our observation showed that ⌬A146 Ply could confer protection against carriage or colonization. Taken together, these findings indicate that it would be more reasonable to use a combination formulation other than pneumolysin alone to achieve a broad protection against pneumococcal infections.
We described and revealed here for the first time the dif- ferential protection pattern elicited by Lpl, ClpP, ⌬A146 Ply, and combinations against intranasal and intraperitoneal pneumococcal infections. Naturally, S. pneumoniae colonizes the upper respiratory tract first and then proliferates and evades the alveolar epithelial capillary endothelium and epithelial basement membrane to cause bacteremia when the host is in a status of hypoimmunity or is immunocompromised. It seems that intranasal challenge more closely imitates natural infection. Accordingly, it would be useful to test whether a vaccine candidate is effective in order to reduce colonization and block the development of bacteremia, especially for pneumococcal vaccine candidates. Apparently, this testing ability was missing in intraperitoneal models. With regard to pneumolysin, for example, if protection was simply based on the intraperitoneal infection model, the protection against bacteremia (data not shown) or against intranasal infection (see Table 3 ) would be lost, since it is widely accepted that pneumolysin plays an important role in this process of bacterial invasion of the bloodstream. Although we emphasize the importance of protection against intranasal infection, we do not completely discount the protection value against intraperitoneal infection, since this model could be also regarded as very important supplementary evidence against a more severe pneumococcal infection. This is a very promising preclinical result, showing a complete protection against pneumococcal infections (i.e., with serotypes 14, 19F, and 23F) in mice that have been vaccinated with the combination vaccine, especially because these are three of the four most clinically important S. pneumoniae serotypes. More importantly, protection elicited by the combination vaccine was as effective as that resulting from the PPV23 and PCV7 vaccines.
We also demonstrated for the first time that this combination could provide protective immunity from acute pneumonia caused by challenge with a mixture of four different pneumococcal strains, since S. pneumoniae often colonizes the nasopharynx with multiple serotypes in a single person (14) . As can be seen in Table 5 , the combination vaccine significantly protected mice from developing bacteremia. Thus, the development of bacteremia in control mice indicated that the observed protection elicited by the combination vaccine was both the result of protection in the lung and protection against the development of bacteremia (Table 5) .
Cell wall separation of group B streptococcus (PcsB) is thus another most promising treatment candidate (13) , since it is involved in the maintenance of cell morphology and is essential for the growth of S. pneumoniae (31, 35) . Immunization with PcsB has shown protective effects in both intranasal and intraperitoneal challenge models. Therefore, it may be promising to combine PcsB with ⌬A146 Ply. Moreover, considering the fact that three is better than two, we may recommend a third candidate in combination with PcsB and ⌬A146 Ply to have a wider coverage and better protection against pneumococcal infections.
